- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07472530
Respiratory Exercises in Frail Elderly COPD Patients
The Effect of Respiratory Exercises on Frailty and Dyspnea in Geriatric Patients With Chronic Obstructive Pulmonary Disease: A Single-Blind Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
This prospective, single-blind, randomized controlled study was conducted between August 2023 and October 2023. A total of 70 patients who presented to the Chest Diseases Outpatient Clinic of Çerkeş State Hospital were enrolled.
T Following a one-month baseline assessment period, 32 patients who did not meet the inclusion criteria were excluded. Stratified randomization was employed to ensure equal assignment to groups based on age, sex, and COPD stage. Group allocations were determined using a computer-based program (random.org), randomly assigning 35 patients to the intervention group and 35 to the control group. Patients were blinded to their group assignments.
Initially, pre-test data were collected from both the intervention and control groups using the measurement instruments prior to the commencement of the exercise program. Subsequently, the intervention group underwent an eight-week exercise program using an incentive spirometer (Triflow) provided by the researchers. Patients were each given the same brand and model of Triflow device (manufactured in Turkey). Practical training on the use of the Triflow was provided, and visual materials prepared by the researcher were given to the patients. Exercise training was administered to the patients in the Chest Diseases Outpatient Clinic by the second author. Patients were instructed to perform the exercise hourly, 10 times per repetition, after waking up at home. The breathing exercise program was evaluated weekly via telephone calls with the patients. No changes were made to the patients' inhaler treatments during the study period.
During the study, one patient in the intervention group withdrew due to death, and another due to the initiation of treatment for pneumonia. A total of 33 patients completed the 8-week exercise program. No exercise regimen was applied to the control group; however, they were contacted regularly each week to inquire about any changes in their health status. Two patients in the control group were lost to follow-up, and therefore their post-test data could not be collected. At the conclusion of the exercise program, the measurement instruments were re-administered to 33 patients in the intervention group and 33 patients in the control group.Data Collection Instruments Data for the research were collected using the "Personal and Medical Characteristics Information Form" developed based on a literature review , along with the Six-Minute Walk Test , Modified Borg Dyspnea Scale , Pulmonary Function Test , and the Edmonton Frailty Scale.
Statistical analyses were carried out using IBM SPSS Statistics version 26. Descriptive data were summarized by calculating means, standard deviations, frequencies, and percentages. The assumptions of normality were assessed through skewness and kurtosis values, with acceptable ranges set at ±1.5 to confirm normal distribution. To assess differences between the intervention and control groups before and after treatment, Independent Samples t-tests were employed. Changes within groups from pre- to post-intervention were evaluated using Paired Samples t-tests. Categorical data comparisons were conducted with Chi-square and Fisher's Exact tests, where appropriate. Statistical significance was set at p < 0.05 for all analyses. Furthermore, A power analysis was conducted using the G*Power 3.1.9.7 software package. Based on the study results, the effect size was calculated as 1.23. Accordingly, with a sample size of 66 participants (33 in the intervention group and 33 in the control group), the study achieved a statistical power of 99.84% at a significance level of α = 0.05.
Ethical principles The authors affirm that all human subject experiments were performed in compliance with the Declaration of Helsinki, and that informed consent was obtained from all participants prior to the procedures. The study was approved by the "This area has been blinded" Ethics Committee (Number: "This area has been blinded"., Date: "This area has been blinded").
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Merkez
-
Çankırı, Merkez, Turkey (Türkiye), 18100
- Çerkeş State Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- a diagnosis of COPD for at least one year prior to participation,
- age 65 years or older,
- normal thoracic and vertebral spine and lower extremities,
- a score of 5 or higher on the Edmonton Frailty Scale,
- no participation in any pulmonary rehabilitation or exercise program within the last year
Exclusion Criteria:
- a history of myocardial infarction within the last 3 months,
- a history of angina pectoris or cerebrovascular event within the last month,
- uncontrolled arrhythmia,
- heart rate >120 beats/min,
- uncontrolled hypertension (BP >180/100 mmHg),
- advanced heart failure (Stage 3/Stage 4),
- severe anemia (Hb <7 g/dL),
- active or chronic infection (COPD exacerbation, Tuberculosis, Osteomyelitis, Rheumatoid Arthritis),
- resting or exertional dyspnea, exertional angina,
- increased cough and sputum complaints within the last week,
- hospitalization within the last month,
- blood transfusion within the last month
- the presence of physical or mental health problems that would impede communication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group Performing Breathing Exercises
Subsequently, the intervention group underwent an eight-week exercise program using an incentive spirometer (Triflow) provided by the researchers.
Patients were each given the same brand and model of Triflow device (manufactured in Turkey).
Practical training on the use of the Triflow was provided, and visual materials prepared by the researcher were given to the patients.
Exercise training was administered to the patients in the Chest Diseases Outpatient Clinic by the second author.
Patients were instructed to perform the exercise hourly, 10 times per repetition, after waking up at home.
The breathing exercise program was evaluated weekly via telephone calls with the patients.
No changes were made to the patients' inhaler treatments during the study period.
|
Initially, pre-test data were collected from both the intervention and control groups using the measurement instruments prior to the commencement of the exercise program.
Subsequently, the intervention group underwent an eight-week exercise program using an incentive spirometer (Triflow) provided by the researchers.
Patients were each given the same brand and model of Triflow device (manufactured in Turkey).
Practical training on the use of the Triflow was provided, and visual materials prepared by the researcher were given to the patients.
Exercise training was administered to the patients in the Chest Diseases Outpatient Clinic by the second author.
Patients were instructed to perform the exercise hourly, 10 times per repetition, after waking up at home [14].
The breathing exercise program was evaluated weekly via telephone calls with the patients.
No changes were made to the patients' inhaler treatments during the study period.
|
|
No Intervention: Control Group without Breathing Exercises
No exercise regimen was applied to the control group; however, they were contacted regularly each week to inquire about any changes in their health status.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary Function Test (PFT)-FVC
Time Frame: 8 WEEKS
|
Forced vital capacity (FVC) is measured in liters.
|
8 WEEKS
|
|
Pulmonary Function Test (PFT)- FEV1
Time Frame: 8 WEEKS
|
Forced inspiratory volume in 1 second (FEV1) is measured in liters.
|
8 WEEKS
|
|
Pulmonary Function Test (PFT)- FEF25-75
Time Frame: 8 WEEKS
|
Forced expiratory flow rate (FEF25-75) is measured in liters/second.
|
8 WEEKS
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Serap KINDAP, MD, Çankırı Karatekin University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Respiratory Tract Diseases
- Lung Diseases
- Respiration Disorders
- Lung Diseases, Obstructive
- Signs and Symptoms, Respiratory
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Frailty
- Pulmonary Disease, Chronic Obstructive
- Dyspnea
- Therapeutics
- Mind-Body Therapies
- Complementary Therapies
- Exercise Movement Techniques
- Physical Therapy Modalities
- Breathing Exercises
Other Study ID Numbers
- 20-06-2023/8
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD (Chronic Obstructive Pulmonary Disease)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Barron Associates, Inc.National Heart, Lung, and Blood Institute (NHLBI); University of VirginiaNot yet recruitingCOPD | COPD - Chronic Obstructive Pulmonary DiseaseUnited States
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Clinical Trials on breathing exercises
-
Derya AzimCompletedStroke | Physiotherapy and RehabilitationTurkey
-
Uppsala UniversityThe Swedish Research Council; Örebro County CouncilCompleted
-
Riphah International UniversityCompleted
-
Rawan Mohammed Khairy Mostafa ElsawyCairo UniversityRecruitingChild, Only | Pulmonary Function | Functional Capacity | Thalassemia Major | Incentive SpirometerEgypt
-
Atlas UniversityCompleted
-
Federal University of BahiaCompletedParkinson Disease | DysphagiaBrazil
-
Naestved HospitalActive, not recruiting
-
Hasan Kalyoncu UniversityCompletedChronic Low-back PainTurkey
-
Lahore University of Biological and Applied SciencesActive, not recruitingStress Urinary Incontinence (SUI)Pakistan
-
Golden Jubilee National HospitalCompletedCoronary Artery Disease | Lung Cancer | Lung TumorUnited Kingdom